NewAmsterdam Pharma Company N.V. (NAMS) Free cash flow 2021–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$148.0MFY2025 · since FY2021: -$29.5M → -$148.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$148.0M | +7.0% |
| FY2024 | -$159.2M | -12.7% |
| FY2023 | -$141.2M | -1452.4% |
| FY2022 | $10.4M | +135.4% |
| FY2021 | -$29.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Operating cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →